Ketamine Assisted EMDR Therapy™ for PTSD: investigating the synergistic effects of pharmacotherapy and psychotherapy

<b>Background:</b> Posttraumatic stress disorder (PTSD) is associated with maladaptive memory reconsolidation and overgeneralized fear responses. EMDR therapy promotes trauma reprocessing by activating the brain's intrinsic memory reconsolidation mechanism, facilitating memory updating, and abandoning outdated emotional schemas. Ketamine may also facilitate adaptive updating of traumatic memory due to its neurobiological and subjective effects. Research remains limited on the combined effects of EMDR therapy and ketamine for PTSD. Ketamine Assisted EMDR Therapy™ (KA-EMDR) integrates low-dose sublingual ketamine with EMDR memory reprocessing, providing a potentially synergistic trauma treatment by improving memory access, reducing hyperarousal, and enhancing adaptive reconsolidation of fear-based memories.<b>Objective:</b> To examine whether incorporating low-dose sublingual ketamine into EMDR therapy reduces PTSD symptom severity and functional impairment in individuals with PTSD.<b>Methods:</b> A retrospective clinical chart review examined data collected from eight clients with PTSD in a private psychotherapy practice who received KA-EMDR. Sublingual ketamine (37.5-75 mg) was self-administered during EMDR reprocessing after memory activation. The International Trauma Questionnaire (ITQ) assessed PTSD symptoms and functional impairment at baseline and after four KA-EMDR reprocessing sessions (T1). Paired-samples t-tests analysed symptom changes. Clients also completed a subjective experience questionnaire.<b>Results:</b> PTSD symptom scores significantly decreased from baseline (<i>M</i> = 15.50, SD = 2.98) to T1 (<i>M</i> = 9.88, SD = 4.94), <i>t</i>(7) = 3.21, <i>p</i> < .05, with a large effect size (<i>g</i> = 1.01). Functional impairment scores significantly declined from baseline (<i>M</i> = 8.50, SD = 2.78) to TI (<i>M</i> = 5.25, SD = 3.24), <i>t</i>(7) = 2.60, <i>p</i> < .05, with a large effect size <i>g</i> = 0.82. Clients reported reduced fear, increased self-compassion and emotional clarity, less resistance, and minimal adverse effects.<b>Conclusions:</b> KA-EMDR may be a promising treatment for PTSD, particularly for those with treatment-resistant trauma. Larger randomized controlled studies are needed to confirm these findings.

Authors

Institutions

Publication Details

Journal
European Journal of Psychotraumatology
Published
2025-11-04
DOI
https://doi.org/10.1080/20008066.2025.2572861
Citations
1
Primary Topic
Treatment of Major Depression
Type
article
Field-Weighted Citation Impact
1.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Ketamine Assisted EMDR Therapy™ for PTSD: investigating the synergistic effects of pharmacotherapy and psychotherapy

Donald S. Ciccone, Michele Topel
1 citations
European Journal of Psychotraumatology
Treatment of Major Depression
1.39
article

Ketamine Assisted EMDR Therapy™ for PTSD: investigating the synergistic effects of pharmacotherapy and psychotherapy

Donald S. Ciccone, Michele Topel
article en
1 citations

Abstract

<b>Background:</b> Posttraumatic stress disorder (PTSD) is associated with maladaptive memory reconsolidation and overgeneralized fear responses. EMDR therapy promotes trauma reprocessing by activating the brain's intrinsic memory reconsolidation mechanism, facilitating memory updating, and abandoning outdated emotional schemas. Ketamine may also facilitate adaptive updating of traumatic memory due to its neurobiological and subjective effects. Research remains limited on the combined effects of EMDR therapy and ketamine for PTSD. Ketamine Assisted EMDR Therapy™ (KA-EMDR) integrates low-dose sublingual ketamine with EMDR memory reprocessing, providing a potentially synergistic trauma treatment by improving memory access, reducing hyperarousal, and enhancing adaptive reconsolidation of fear-based memories.<b>Objective:</b> To examine whether incorporating low-dose sublingual ketamine into EMDR therapy reduces PTSD symptom severity and functional impairment in individuals with PTSD.<b>Methods:</b> A retrospective clinical chart review examined data collected from eight clients with PTSD in a private psychotherapy practice who received KA-EMDR. Sublingual ketamine (37.5-75 mg) was self-administered during EMDR reprocessing after memory activation. The International Trauma Questionnaire (ITQ) assessed PTSD symptoms and functional impairment at baseline and after four KA-EMDR reprocessing sessions (T1). Paired-samples t-tests analysed symptom changes. Clients also completed a subjective experience questionnaire.<b>Results:</b> PTSD symptom scores significantly decreased from baseline (<i>M</i> = 15.50, SD = 2.98) to T1 (<i>M</i> = 9.88, SD = 4.94), <i>t</i>(7) = 3.21, <i>p</i> < .05, with a large effect size (<i>g</i> = 1.01). Functional impairment scores significantly declined from baseline (<i>M</i> = 8.50, SD = 2.78) to TI (<i>M</i> = 5.25, SD = 3.24), <i>t</i>(7) = 2.60, <i>p</i> < .05, with a large effect size <i>g</i> = 0.82. Clients reported reduced fear, increased self-compassion and emotional clarity, less resistance, and minimal adverse effects.<b>Conclusions:</b> KA-EMDR may be a promising treatment for PTSD, particularly for those with treatment-resistant trauma. Larger randomized controlled studies are needed to confirm these findings.

European Journal of PsychotraumatologyVol. 16(1)
Kemin (Belgium) (BE)
Openalex Percentile: Top 15%
Treatment of Major Depression
1.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.